Skip to main
SRRK
SRRK logo

SRRK Stock Forecast & Price Target

SRRK Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Scholar Rock Holding Corp has shown positive market momentum, with shares increasing approximately 4% following recent news. The company's management successfully addressed production observations at a contract development and manufacturing organization (CDMO) facility, enhancing confidence in their operational capabilities. Furthermore, despite encountering a complete response letter (CRL), there remains strong long-term conviction in apitegromab's potential as a multi-blockbuster therapy due to its robust clinical profile in addressing a significant unmet medical need.

Bears say

Scholar Rock Holding Corp faces significant challenges as the commercial launch of its lead candidate, apitegromab, has been postponed from Q4 2025 to Q2 2026 for the US market and from Q2 2026 to Q3 2026 for the EU market due to regulatory delays. The issuance of a Complete Response Letter (CRL) necessitates a resubmission of the Biologics License Application (BLA) to the FDA, indicating a setback for the company that could adversely affect anticipated revenue timelines. This delay contributes to a recalibration of financial models, resulting in a slight decrease in projections, which casts uncertainty over the company's near-term financial outlook amidst its operational challenges.

SRRK has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Scholar Rock Holding Corp (SRRK) Forecast

Analysts have given SRRK a Buy based on their latest research and market trends.

According to 8 analysts, SRRK has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Scholar Rock Holding Corp (SRRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.